Clinical Trial Search

Primary: Number of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75% Improvement at Week 12 — 1; 33; 38; 43 Participants — p=<0.001

Primary: Change From Baseline in 2-h Postprandial Glucose (Breakfast, Lunch and Dinner) — -56.2; -43.7; -5.5; -43.1 mg / dL

Primary: Change in Non-HDL Cholesterol Level for Patients Assigned to Stay and Patients Assigned to Switch Over 24 Weeks — -20.2; -10.8 mg/dL non-HDL cholesterol

Primary: NRS Pain Score AUC (NRS*hr) - 1st 24 Hours — 70.4; 59.6; 73.4 Area (NRS*hr) — p=0.4742

Primary: Percent of Subjects Without Recurrence of Diverticulitis — 62.8; 59.2; 69.1; 67.6 percentage of subjects — p=0.778

Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] — 396 nanogram*hour/milliliter (ng*hr/mL)

Primary: Change in BMI Standard Deviation Score — -0.12; -0.06 Standard Deviation Score — p=0.007

Primary: Analgesia/Nociception Index (ANI) — 73; 49 units on a scale

Primary: Complete Response Rate at the End of Induction — 46 percentage of participants

Primary: Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26) — 44.1; 11.4 Percentage — p=<.0001

Primary: Number of Participants Who Experienced at Least One Adverse Event — 4; 11; 7; 8 participants

Primary: Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12 — 6.36; 2.73 percentage change in FMD

Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants

Primary: Geometric Least Square Means of Area Under the Curve (AUC) for Plasma Total Immunoglobulin G (IgG) — 7549; 6706 mg*hr/ml

Primary: Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Week 6 — 97.1 Percentage of participants